Navidea Biopharmaceuticals Inc (NAVB)

[casperboo]

Regardless of how much the head and neck approval will or will not boost the stock, a denial on June 16th could certainly crush it below 1.00. If we get all 3 approvals (including Europe and the October decision) we should recover to somewhere in the mid 2s - especially if the company can find the time to provide a MEANINGFUL update on 4694, 5001, or 1800 - or perhaps they are working with the shorts outright. Nothing surprises me anymore with this sham of a company.

It sure seems as if the company could care less about shareholder value.